Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 96 articles:
HTML format
Text format



Single Articles


    April 2017
  1. SIMONIN M, Dalissier A, Labopin M, Willasch A, et al
    More chronic GvHD and non-relapse mortality after peripheral blood stem cell compared with bone marrow in hematopoietic transplantation for paediatric acute lymphoblastic leukemia: a retrospective study on behalf of the EBMT Paediatric Diseases Workin
    Bone Marrow Transplant. 2017 Apr 10. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  2. YAMASAKI S, Suzuki R, Hatano K, Fukushima K, et al
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  3. SELLNER L, Bruggemann M, Schlitt M, Knecht H, et al
    GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
    Bone Marrow Transplant. 2017;52:656.
    PubMed     Text format    


    February 2017
  4. O'HARE P, Lucchini G, Cummins M, Veys P, et al
    Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience.
    Bone Marrow Transplant. 2017 Feb 20. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    January 2017
  5. YANADA M, Kurosawa S, Kobayashi T, Ozawa Y, et al
    Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study.
    Bone Marrow Transplant. 2017 Jan 23. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  6. ROUX C, Tifratene K, Socie G, Galambrun C, et al
    Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the societe Francophone de greffe de moelle et de therapie cellulaire (SFGM-TC).
    Bone Marrow Transplant. 2017 Jan 23. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  7. BATTIPAGLIA G, Labopin M, Candoni A, Fanin R, et al
    Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  8. CAI WZ, Cen JN, Chen J, Chen F, et al
    Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  9. FUJIWARA H, Fuji S, Wake A, Kato K, et al
    Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  10. TODISCO E, Ciceri F, Boschini C, Giglio F, et al
    Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    December 2016
  11. BUCCISANO F, Maurillo L, Piciocchi A, Del Principe MI, et al
    Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  12. ALLOIN AL, Leverger G, Dalle JH, Galambrun C, et al
    Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  13. SELLNER L, Bruggemann M, Schlitt M, Knecht H, et al
    GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  14. TSIRIGOTIS P, Liga M, Gkirkas K, Stamouli M, et al
    Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  15. EL BOGHDADLY Z, Oran B, Jiang Y, Rondon G, et al
    Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  16. CHEN YB, Wang T, Hemmer MT, Brady C, et al
    GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    September 2016
  17. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  18. BRAMMER JE, Saliba RM, Jorgensen JL, Ledesma C, et al
    Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.
    Bone Marrow Transplant. 2016 Sep 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  19. SIRVENT A, Auquier P, Oudin C, Bertrand Y, et al
    Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.
    Bone Marrow Transplant. 2016 Sep 5. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    August 2016
  20. CHO WK, Ahn MB, Lee JW, Chung NG, et al
    Low bone mineral density in adolescents with leukemia after hematopoietic stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic stem cell transplantation might be major concerns?
    Bone Marrow Transplant. 2016 Aug 1. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    June 2016
  21. SUN W, Gao F, Guo W, Wang B, et al
    Focused extracorporeal shock wave for osteonecrosis of the femoral head with leukemia after allo-HSCT: a case series.
    Bone Marrow Transplant. 2016 Jun 6. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    May 2016
  22. ADMIRAAL R, Chiesa R, Lindemans CA, Nierkens S, et al
    Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    April 2016
  23. KOENECKE C, Heim D, van Biezen A, Heuser M, et al
    Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  24. HOCHBERG J, Harrison L, Morris E, Militano O, et al
    Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 Apr 18. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  25. PERL AE, Luger SM
    Allogeneic transplant for FLT3-ITD+ AML: room for improvement.
    Bone Marrow Transplant. 2016;51:508-10.
    PubMed     Text format    


  26. RUGGERI A, Labopin M, Ciceri F, Mohty M, et al
    Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission.
    Bone Marrow Transplant. 2016;51:610-1.
    PubMed     Text format    


  27. DEFILIPP Z, Purcell M, Harris WA, Chandra DJ, et al
    Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.
    Bone Marrow Transplant. 2016;51:607-9.
    PubMed     Text format    


  28. MOGHNIEH R, Fawaz I, Mugharbil A, Jisr T, et al
    Clinical outcome and adverse events associated with empiric and pre-emptive use of amphotericin B lipid complex in a single center in lebanon.
    Bone Marrow Transplant. 2016;51:598-600.
    PubMed     Text format    


  29. SONG Y, Magenau J, Li Y, Braun T, et al
    FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.
    Bone Marrow Transplant. 2016;51:511-20.
    PubMed     Text format     Abstract available


    March 2016
  30. BARON F, Beguin Y
    Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?
    Bone Marrow Transplant. 2016 Mar 14. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  31. CHANG X, Zang X, Xia CQ
    New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.
    Bone Marrow Transplant. 2016;51:324-32.
    PubMed     Text format     Abstract available


    February 2016
  32. ARITA K, Murakami J, Wada A, Miyazono T, et al
    Changes in the autoantibody pattern during allogeneic stem-cell transplantation for acute myeloid leukemia complicated by systemic lupus erythematosus.
    Bone Marrow Transplant. 2016 Feb 22. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  33. VAN GELDER M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, et al
    Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.
    Bone Marrow Transplant. 2016 Feb 15. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  34. CHRISTOPEIT M
    When is second allogeneic HSCT for relapse of acute leukaemia an option?
    Bone Marrow Transplant. 2016;51:184-5.
    PubMed     Text format    


  35. DEVILLIER R, Bramanti S, Furst S, Sarina B, et al
    T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.
    Bone Marrow Transplant. 2016;51:194-8.
    PubMed     Text format     Abstract available


  36. VRHOVAC R, Labopin M, Ciceri F, Finke J, et al
    Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.
    Bone Marrow Transplant. 2016;51:186-93.
    PubMed     Text format     Abstract available


    January 2016
  37. MASCHAN M, Shelikhova L, Ilushina M, Kurnikova E, et al
    TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia.
    Bone Marrow Transplant. 2016 Jan 25. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  38. BLEYZAC N, Cuzzubbo D, Renard C, Garnier N, et al
    Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.
    Bone Marrow Transplant. 2016 Jan 25. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  39. MIZUTANI M, Hara M, Fujita H, Aoki J, et al
    Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.
    Bone Marrow Transplant. 2016 Jan 25. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  40. LIANG CS, Quesada AE, Goswami M, Johnston PK, et al
    Phosphorylated STAT3 expression in hematopoietic stem cell transplant-associated large granular lymphocytic leukemia.
    Bone Marrow Transplant. 2016 Jan 11. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  41. NISHIWAKI S, Imai K, Mizuta S, Kanamori H, et al
    Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.
    Bone Marrow Transplant. 2016;51:43-50.
    PubMed     Text format     Abstract available


    December 2015
  42. AOKI J, Seo S, Kanamori H, Tanaka M, et al
    Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML.
    Bone Marrow Transplant. 2015 Dec 7. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  43. XUE E, Tresoldi C, Sala E, Crippa A, et al
    Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse.
    Bone Marrow Transplant. 2015 Dec 7. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  44. GALE RP, Apperley JF
    Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same.
    Bone Marrow Transplant. 2015;50:1582.
    PubMed     Text format    


    November 2015
  45. CAHU X, Labopin M, Giebel S, Aljurf M, et al
    Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.
    Bone Marrow Transplant. 2015 Nov 30. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  46. RASHIDI A, DiPersio JF, Westervelt P, Abboud CN, et al
    Acute myeloid leukemia presenting with extensive bone marrow necrosis, leukemia cutis and testicular involvement: successful treatment with allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2015 Nov 9. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  47. HAJI S, Kiyasu J, Choi I, Suehiro Y, et al
    Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2015 Nov 2. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  48. FUJI S, Fujiwara H, Nakano N, Wake A, et al
    Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2015 Nov 2. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    October 2015
  49. PENACK O, Tridello G, Hoek J, Socie G, et al
    Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.
    Bone Marrow Transplant. 2015 Oct 26. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    September 2015
  50. ANDREOLA G, Labopin M, Beelen D, Chevallier P, et al
    Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years.
    Bone Marrow Transplant. 2015 Sep 21. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  51. KROGER N, Bornhauser M, Stelljes M, Pichlmeier U, et al
    Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
    Bone Marrow Transplant. 2015 Sep 14. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  52. CHANTEPIE SP, Michallet M, Blaise D, Maury S, et al
    Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy.
    Bone Marrow Transplant. 2015 Sep 14. doi: 10.1038/bmt.2015.
    PubMed     Text format    


    August 2015
  53. GORIN NC, Giebel S, Labopin M, Savani BN, et al
    Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects.
    Bone Marrow Transplant. 2015 Aug 17. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  54. RELJIC T, Kumar A, Djulbegovic B, Kharfan-Dabaja MA, et al
    High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review.
    Bone Marrow Transplant. 2015;50:1144.
    PubMed     Text format    


    July 2015
  55. OUDIN C, Auquier P, Bertrand Y, Contet A, et al
    Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study.
    Bone Marrow Transplant. 2015 Jul 20. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  56. HAHN M, Bottcher S, Dietrich S, Hegenbart U, et al
    Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.
    Bone Marrow Transplant. 2015 Jul 6. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    June 2015
  57. KRUCHEN A, Stahl T, Gieseke F, Binder TM, et al
    Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients.
    Bone Marrow Transplant. 2015 Jun 22. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  58. KUROSAWA S, Yamaguchi T, Mori T, Kanamori H, et al
    Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia.
    Bone Marrow Transplant. 2015 Jun 15. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  59. WATANABE S, Waseda Y, Kimura H, Takato H, et al
    Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2015 Jun 8. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  60. YEW PY, Alachkar H, Yamaguchi R, Kiyotani K, et al
    Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2015 Jun 8. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  61. O'REILLY RJ, Koehne G, Hasan AN, Doubrovina E, et al
    T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.
    Bone Marrow Transplant. 2015;50 Suppl 2:S43-50.
    PubMed     Text format     Abstract available


  62. PASSWEG JR, Labopin M, Cornelissen J, Volin L, et al
    Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2015 Jun 1. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  63. BONINI C, Peccatori J, Stanghellini MT, Vago L, et al
    Haploidentical HSCT: a 15-year experience at San Raffaele.
    Bone Marrow Transplant. 2015;50 Suppl 2:S67-71.
    PubMed     Text format     Abstract available


  64. MARTELLI MF, Ianni MD, Ruggeri L, Falzetti F, et al
    Next generation HLA-haploidentical HSCT.
    Bone Marrow Transplant. 2015;50 Suppl 2:S63-6.
    PubMed     Text format     Abstract available


  65. LANG P, Feuchtinger T, Teltschik HM, Schwinger W, et al
    Improved immune recovery after transplantation of TCRalphabeta/CD19-depleted allografts from haploidentical donors in pediatric patients.
    Bone Marrow Transplant. 2015;50 Suppl 2:S6-10.
    PubMed     Text format     Abstract available


  66. CHANG YJ, Huang XJ
    Improving the clinical outcome of unmanipulated haploidentical blood and marrow transplantation.
    Bone Marrow Transplant. 2015;50 Suppl 2:S21-3.
    PubMed     Text format     Abstract available


  67. AVERSA F
    T-cell depletion: from positive selection to negative depletion in adult patients.
    Bone Marrow Transplant. 2015;50 Suppl 2:S11-3.
    PubMed     Text format     Abstract available


  68. REISNER Y, Aversa F, Martelli MF
    Haploidentical hematopoietic stem cell transplantation: state of art.
    Bone Marrow Transplant. 2015;50 Suppl 2:S1-5.
    PubMed     Text format     Abstract available


  69. KAWANO H, Tanaka H, Yamashita T, Hirata KI, et al
    Very late-onset reversible cardiomyopathy in patients with chronic GvHD.
    Bone Marrow Transplant. 2015;50:870-2.
    PubMed     Text format    


  70. RESHEF R, Porter DL
    Reduced-intensity conditioned allogeneic SCT in adults with AML.
    Bone Marrow Transplant. 2015;50:759-69.
    PubMed     Text format     Abstract available


    May 2015
  71. PAN Y, Wang X, Wang C, Zhang Q, et al
    Extensive bone marrow necrosis resolved by allogeneic umbilical cord blood mesenchymal stem cell transplantation in a chronic myeloid leukemia patient.
    Bone Marrow Transplant. 2015 May 11. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  72. STEINMANN J, Bertz H, Wasch R, Marks R, et al
    5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft.
    Bone Marrow Transplant. 2015;50:690-5.
    PubMed     Text format     Abstract available


  73. ALDOSS I, Dagis A, Palmer J, Forman S, et al
    Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome.
    Bone Marrow Transplant. 2015;50:746-8.
    PubMed     Text format    


  74. GOSWAMI M, McGowan KS, Lu K, Jain N, et al
    A multigene array for measurable residual disease detection in AML patients undergoing SCT.
    Bone Marrow Transplant. 2015;50:642-51.
    PubMed     Text format     Abstract available


  75. VAXMAN I, Ram R, Gafter-Gvili A, Vidal L, et al
    Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis.
    Bone Marrow Transplant. 2015;50:706-14.
    PubMed     Text format     Abstract available


    April 2015
  76. HOBBS GS, Hamdi A, Hilden PD, Goldberg JD, et al
    Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.
    Bone Marrow Transplant. 2015;50:493-8.
    PubMed     Text format     Abstract available


  77. WILK CM, Fischer JC, Schieren G, Rox JM, et al
    Treatment of donor-specific antibody-mediated graft rejection by immunochemotherapy, third-party DLI, plasmapheresis and immunoadsorption.
    Bone Marrow Transplant. 2015;50:613-4.
    PubMed     Text format    


  78. SAUER T, Silling G, Groth C, Rosenow F, et al
    Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT.
    Bone Marrow Transplant. 2015;50:485-92.
    PubMed     Text format     Abstract available


  79. DE BRITO MD, Campilho F, Branca R, Vaz CP, et al
    Inadvertent transmission of occult CML through allo-SCT.
    Bone Marrow Transplant. 2015;50:598.
    PubMed     Text format    


    March 2015
  80. NIKOLAJEVA O, Mijovic A, Hess D, Tatam E, et al
    Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience.
    Bone Marrow Transplant. 2015 Mar 30. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  81. HARVEY J, Green A, Groves SJ, Cornish J, et al
    Correlation between microsatellite discrepancy scores and transplant outcome after haemopoietic SCT for pediatric ALL.
    Bone Marrow Transplant. 2015;50:363-6.
    PubMed     Text format     Abstract available


  82. BEIER R, Maecker-Kolhoff B, Sykora KW, Chao M, et al
    Minimal antileukaemic treatment followed by reduced-intensity conditioning in three consecutive children with Fanconi anaemia and AML.
    Bone Marrow Transplant. 2015;50:463-4.
    PubMed     Text format    


  83. KIM M, Park J, Kim DW, Kim YJ, et al
    Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
    Bone Marrow Transplant. 2015;50:354-62.
    PubMed     Text format     Abstract available


  84. GUILCHER GM, Moorjani R, Truong TH, Lewis VA, et al
    Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
    Bone Marrow Transplant. 2015;50:455-6.
    PubMed     Text format    


    February 2015
  85. ARAI Y, Kondo T, Kitano T, Hishizawa M, et al
    Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation.
    Bone Marrow Transplant. 2015;50:312-4.
    PubMed     Text format    


  86. JAIN NA, Ito S, Tian X, Kurlander R, et al
    Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.
    Bone Marrow Transplant. 2015;50:189-96.
    PubMed     Text format     Abstract available


    January 2015
  87. MO XD, Xu LP, Zhang XH, Liu DH, et al
    Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2015;50:127-33.
    PubMed     Text format     Abstract available


  88. GHISO A, Raiola AM, Gualandi F, Dominietto A, et al
    DLI after haploidentical BMT with post-transplant CY.
    Bone Marrow Transplant. 2015;50:56-61.
    PubMed     Text format     Abstract available


  89. SOMMER IE, van Bekkum DW, Klein H, Yolken R, et al
    Severe chronic psychosis after allogeneic SCT from a schizophrenic sibling.
    Bone Marrow Transplant. 2015;50:153-4.
    PubMed     Text format    


  90. FUJI S, Mori T, Khattry N, Cheng J, et al
    Severe weight loss in 3 months after allogeneic hematopoietic SCT was associated with an increased risk of subsequent non-relapse mortality.
    Bone Marrow Transplant. 2015;50:100-5.
    PubMed     Text format     Abstract available


  91. DE CASTRO CG JR, Ganc AJ, Ganc RL, Petrolli MS, et al
    Fecal microbiota transplant after hematopoietic SCT: report of a successful case.
    Bone Marrow Transplant. 2015;50:145.
    PubMed     Text format    


  92. SALHOTRA A, Tsai N, Thomas SH, Paris T, et al
    Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2015;50:139-41.
    PubMed     Text format    


  93. SEBERT M, Porcher R, Robin M, Ades L, et al
    Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML.
    Bone Marrow Transplant. 2015;50:74-81.
    PubMed     Text format     Abstract available


  94. SUN YQ, Wang J, Jiang Q, Xu LP, et al
    Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL.
    Bone Marrow Transplant. 2015;50:20-5.
    PubMed     Text format     Abstract available


    November 2014
  95. HENGEVELD M, Suciu S, Chelgoum Y, Marie JP, et al
    High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.
    Bone Marrow Transplant. 2014 Nov 17. doi: 10.1038/bmt.2014.
    PubMed     Text format     Abstract available


  96. ELZE MC, Ciocarlie O, Heinze A, Kloess S, et al
    Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2014 Nov 10. doi: 10.1038/bmt.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: